Cargando…

Patient experiences of conservative treatment for early stage endometrial cancer and endometrial hyperplasia with atypia using levonorgestrel intrauterine device: A qualitative study

OBJECTIVE: The aim of the study was to obtain an in-depth understanding of the experience of women who received non-surgical treatment for endometrial adenocarcinoma (EAC) or endometrial hyperplasia with atypia (EHA). Enhanced understanding of women’s experiences of non-surgical treatment is essenti...

Descripción completa

Detalles Bibliográficos
Autores principales:	O'Hara, Montana, Janda, Monika, McCarthy, Alexandra L., Nicklin, James, Walker, Graeme, Obermair, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718559/ https://www.ncbi.nlm.nih.gov/pubmed/35005158 http://dx.doi.org/10.1016/j.gore.2021.100914

Ejemplares similares

Comparison of the effectiveness of the levonorgestrel-intrauterine device and oral progestogens on regression of endometrial hyperplasia without atypia
por: Shen, Ye, et al.
Publicado: (2022)

A Randomized Clinical Trial of Levonorgestrel Intrauterine System with or without Metformin for Treatment of Endometrial Hyperplasia without Atypia in Indian Women
por: Dinnekere Ravi, Ramya, et al.
Publicado: (2021)

Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial*
por: Ørbo, A, et al.
Publicado: (2014)

Paucity of data evaluating patient centred outcomes following sentinel lymph node dissection in endometrial cancer: A systematic review
por: Obermair, Helena M., et al.
Publicado: (2021)

The value of MRI in management of endometrial hyperplasia with atypia
por: Natarajan, Purushothaman, et al.
Publicado: (2020)

Conservative management of endometrial hyperplasia or carcinoma with the levonorgestrel intrauterine system may be less effective in morbidly obese patients
por: Graul, Ashley, et al.
Publicado: (2018)

Efficacy of Oral Medications or Intrauterine Device-Delivered Progestin in Patients with Endometrial Hyperplasia with or without Atypia: A Network Meta-Analysis
por: Zhang, Yu-Fei, et al.
Publicado: (2023)

Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia
por: Behnamfar, Fariba, et al.
Publicado: (2014)

Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel‐impregnated intrauterine system or oral progestogens
por: Ørbo, A, et al.
Publicado: (2015)

The current situation of the levonorgestrel intrauterine system (LNG-IUS) in conservative treatment for patients with early-stage endometrial cancer and atypical hyperplasia
por: Chen, Xiaojun
Publicado: (2019)

Comparison of Mirena and Liletta levonorgestrel intrauterine devices for the treatment of endometrial intraepithelial neoplasia and grade 1 endometrioid endometrial cancer
por: Chaudhari, Sonal R., et al.
Publicado: (2023)

Dienogest versus norethisterone acetate in management of endometrial hyperplasia without atypia
por: Girbash, Ehab F., et al.
Publicado: (2023)

Non-atypical endometrial hyperplasia: risk factors for occult endometrial atypia and malignancy in patients managed with hysterectomy
por: Hui, Lee Shi, et al.
Publicado: (2021)

MicroRNAs as Predictors of Future Uterine Malignancy in Endometrial Hyperplasia without Atypia
por: Lin, Chiao-Yun, et al.
Publicado: (2022)

Progestin Intrauterine Devices and Metformin: Endometrial Hyperplasia and Early Stage Endometrial Cancer Medical Management
por: Nwanodi, Oroma
Publicado: (2017)

Fertility-Sparing Treatment for Endometrial Cancer: Oncological and Obstetric Outcomes in Combined Therapies with Levonorgestrel Intrauterine Device
por: Pino, Ida, et al.
Publicado: (2022)

Weight-Loss Interventions and Levonorgestrel Intrauterine System Implantation for Early-Stage Endometrial Cancer and Atypical Endometrial Hyperplasia to Reduce Perioperative Risk of Severely Obese Patients
por: Isono-Taniguchi, Roze, et al.
Publicado: (2023)

Segmented in vitro fertilization and frozen embryo transfer in levonorgestrel-releasing intrauterine device treated patients with endometrial cancer
por: Wei, Hongyi, et al.
Publicado: (2023)

Medically unfit women with early-stage endometrial cancer treated with the levonorgestrel intrauterine system
por: Nikolopoulos, Manolis, et al.
Publicado: (2020)

Development of endometrial cancer after long-term usage of the levonorgestrel-releasing intrauterine system
por: Steshenko, Alexander, et al.
Publicado: (2021)

Endometrial Cancer Following Levonorgestrel-Releasing Intrauterine System Insertion in Young Women with Atypical Hyperplasia: Two Case Reports and Literature Review
por: Peng, Hongfa, et al.
Publicado: (2022)

Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol
por: Zhao, Xin, et al.
Publicado: (2022)

Levonorgestrel-IUS system and endometrial manipulation
por: Malik, Sonia
Publicado: (2013)

Correction of Phrase: Medically unfit women with earlystage endometrial cancer treated with the levonorgestrel intrauterine system
por: Nikolopoulos, Manolis, et al.
Publicado: (2020)

The levonorgestrel intrauterine system versus endometrial ablation for heavy menstrual bleeding: a cost‐effectiveness analysis
por: van den Brink, MJ, et al.
Publicado: (2021)

Characterisation of Levonorgestrel-Resistant Endometrial Cancer Cells
por: Dore, Molly, et al.
Publicado: (2021)

Baseline Serum HE4 But Not Tissue HE4 Expression Predicts Response to the Levonorgestrel-Releasing Intrauterine System in Atypical Hyperplasia and Early Stage Endometrial Cancer
por: Behrouzi, Roya, et al.
Publicado: (2020)

Intrauterine device use and risk of endometrial cancer.
por: Parazzini, F., et al.
Publicado: (1994)

Can a symptom checklist improve the triage of patients following successful endometrial cancer treatment?
por: Peng, Yang, et al.
Publicado: (2020)

Prostatic Stromal Hyperplasia with Atypia
por: Hutchinson, Ryan C., et al.
Publicado: (2013)

Hysterectomy, endometrial ablation, and levonorgestrel releasing intrauterine system (Mirena) for treatment of heavy menstrual bleeding: cost effectiveness analysis
por: Roberts, T E, et al.
Publicado: (2011)

Levonorgestrel-releasing intrauterine system-based therapies for early-stage endometrial cancer: a systematic review and meta-analysis
por: Wei, Hongyi, et al.
Publicado: (2023)

Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women
por: Uccella, Stefano, et al.
Publicado: (2022)

Dilatation and curettage is more accurate than endometrial aspiration biopsy in early-stage endometrial cancer patients treated with high dose oral progestin and levonorgestrel intrauterine system
por: Kim, Da Hee, et al.
Publicado: (2017)

Levonorgestrel-Releasing Intrauterine Device-Related Acute Liver Injury
por: Cheema, Hira Imad, et al.
Publicado: (2017)

Use of the Levonorgestrel Intrauterine Device in Women With Type 2 Diabetes
por: Lang, Benjamin, et al.
Publicado: (2018)

Clinical Evaluation of Li Brush Endometrial Samplers for Diagnosing Endometrial Lesions in Women With Intrauterine Devices
por: Han, Lu, et al.
Publicado: (2020)

Pregnancy outcomes of women who received conservative therapy for endometrial carcinoma or atypical endometrial hyperplasia
por: Matsuzaki, Toshiya, et al.
Publicado: (2018)

Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasia
por: Chen, Junyu, et al.
Publicado: (2022)

Differential Effects of the Hormonal and Copper Intrauterine Device on the Endometrial Transcriptome
por: Smith-McCune, Karen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_528je2e4lfjnubr22jmueq25k4